Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | IDH1 | O75874 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | DHODH | Q02127 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142563 | 0.87 | POLB (0.54) | POLBLMNATDP1IDH1HTT | |
| SCHEMBL5113179 | 0.86 | POLB (0.53) | POLBALDH1A1LMNATDP1MAPT | |
| SCHEMBL28658507 | 0.86 | POLB (0.52) | POLBALDH1A1LMNATDP1IDH1 | |
| Hydrochloric Acid SCHEMBL5775146 | 0.85 | POLB (0.51) | POLBALDH1A1LMNATDP1MAPT | |
| SCHEMBL9830208 | 0.84 | ALDH1A1 (0.51) | POLBALDH1A1LMNAMAPTHTT | |
| SCHEMBL11355645 | 0.83 | POLB (0.55) | POLBALDH1A1LMNAIDH1MAPT | |
| SCHEMBL11471191 | 0.82 | POLB (0.48) | POLBALDH1A1LMNATDP1MAPT | |
| SCHEMBL6906565 | 0.82 | POLB (0.55) | POLBLMNATDP1IDH1HTT | |
| SCHEMBL29148948 | 0.81 | POLB (0.61) | POLBLMNAIDH1MAPTHTT | |
| SCHEMBL4035087 | 0.81 | POLB (0.65) | POLBALDH1A1TDP1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117447339-A | Method for preparing alkyl substituted glycine derivative by driving visible light | 沈阳师范大学 | 2024-01-26 | — | — | CN | disclosed |
| EP-3560928-B1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| CN-108203438-B | Fused imidazole compounds having indoleamine 2,3-dioxygenase inhibitory activity | 深圳微芯生物科技股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2020-03-31 | — | — | US | disclosed |
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3560928-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018113624-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | 深圳微芯生物科技有限责任公司 | 2018-06-28 | — | — | WO | disclosed |
| EP-0721944-B1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LTD (JP) | 2001-01-17 | — | — | EP | disclosed |
| US-5691335-A | CARDIOVASCULAR DISORDERS | SUNTORY LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0721944-A1 | IMIDAZOLIDINE DERIVATIVE AND USE THEREOF | SUNTORY LIMITED (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352307-A1 | FUSED IMIDAZOLE COMPOUND HAVING INDOLEAMINE 2,3-DIOXYGENASE INHIBITORY ACTIVITY | IDO1, IDO2, INMT | POLB 3522/4885ALDH1A1 735/4885LMNA 4703/4885 |
| US-10604529-B2 | Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity | IDO1, IDO2, INMT | POLB 3731/4885ALDH1A1 376/4885LMNA 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.